Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
Centre Antoine Lacassagne · Institut Curie · +3 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
603
total citations
- FWCI
- 56.25
- Percentile
- 100%
- References
- 24
Citations per year
Authors
14Topics & keywords
Topics
Keywords
- Medicine
- Nivolumab
- Head and neck squamous-cell carcinoma
- Internal medicine
- Oncology
- Immunotherapy
- Head and neck cancer
- Tumor progression
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.